Answers are grounded in this paper and cite their sources.
In patients who had an inadequate response to or had unacceptable side effects from hydroxyurea, ruxolitinib was superior to standard therapy in controlling the hematocrit, reducing the spleen volume, and improving symptoms associated with polycythemia vera. (Funded by Incyte and others; RESPONSE ClinicalTrials.gov number, NCT01243944.).
No takes yet. Share an insight, caveat, or question.
Vannucchi et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: